pantoprazole has been researched along with Diabetes Mellitus, Adult-Onset in 10 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty-six consecutive patients with type 2 diabetes mellitus and 58 age- and sex-matched control patients were included in the study." | 2.74 | Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. ( Arslan, H; Demir, M; Gokturk, HS; Ozturk, NA; Serin, E; Yilmaz, U, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grong, E | 1 |
| Nord, C | 1 |
| Arbo, IB | 1 |
| Eriksson, M | 1 |
| Kulseng, BE | 1 |
| Ahlgren, U | 1 |
| Mårvik, R | 1 |
| Inci, F | 1 |
| Atmaca, M | 1 |
| Ozturk, M | 1 |
| Yildiz, S | 1 |
| Koceroglu, R | 1 |
| Sekeroglu, R | 1 |
| Ipekci, SH | 1 |
| Kebapcilar, L | 1 |
| González-Ortiz, M | 1 |
| Martínez-Abundis, E | 1 |
| Mercado-Sesma, AR | 1 |
| Álvarez-Carrillo, R | 1 |
| Sapmaz, F | 1 |
| Kalkan, IH | 1 |
| Suslu, I | 1 |
| Demirci, H | 1 |
| Atasoy, P | 1 |
| Guliter, S | 1 |
| Demir, M | 4 |
| Gokturk, HS | 2 |
| Ozturk, NA | 3 |
| Arslan, H | 1 |
| Serin, E | 3 |
| Yilmaz, U | 3 |
| Göktürk, S | 1 |
| Ataseven, H | 1 |
| Gen, R | 1 |
| Singh, PK | 1 |
| Hota, D | 1 |
| Dutta, P | 1 |
| Sachdeva, N | 1 |
| Chakrabarti, A | 1 |
| Srinivasan, A | 1 |
| Singh, I | 1 |
| Bhansali, A | 1 |
| Rickels, MR | 1 |
| Elahi, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Pantoprazole on Insulin Secretion in Patients With Type 2 Diabetes[NCT01541735] | Phase 2/Phase 3 | 14 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| A Phase IIB/III Multicenter Randomized Trial to Evaluate the Combination of Low-Dose Cyclosporine and Omeprazole Versus Omeprazole Alone in Participants With New Onset Type 1 Diabetes.[NCT01762644] | Phase 3 | 0 participants (Actual) | Interventional | 2015-08-31 | Withdrawn (stopped due to This study was withdrawn prior to enrollment.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The hyperglycemic-hyperinsulinemic clamp technique is perform to assess the phases of insulin secretion: first, late and total insulin secretion. (NCT01541735)
Timeframe: Change from Baseline at 45 days. (plus or minus 3 days)
| Intervention | µU/ml (Mean) |
|---|---|
| Pantoprazole | 13.8 |
| Placebo | 15.9 |
(NCT01541735)
Timeframe: Change from Baseline in glycated hemoglobin A1C at 45 day.
| Intervention | percentage (Mean) |
|---|---|
| Pantoprazole | 7.5 |
| Placebo | 7.8 |
Change from baseline in first phase insulin secretion at 45 day. (plus or minus 3 days) (NCT01541735)
Timeframe: Baseline and 45 day
| Intervention | µU/ml (Mean) |
|---|---|
| Pantoprazole | 35.9 |
| Placebo | 38.4 |
The hyperglycemic-hyperinsulinemic clamp technique is performed to assess the total insulin secretion (NCT01541735)
Timeframe: Change from baseline of total insulin secretion at 45 day (plus or minus 3 days)
| Intervention | µU/ml (Mean) |
|---|---|
| Pantoprazole | 29.0 |
| Placebo | 31.5 |
6 trials available for pantoprazole and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Respo | 2015 |
Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diabete | 2009 |
Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2009 |
Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infectiv | 2010 |
Effect of sequential treatment as a first-line therapy for Helicobacter pylori eradication in patients with diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Diab | 2010 |
Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Doub | 2012 |
4 other studies available for pantoprazole and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
The effect of hypergastrinemia following sleeve gastrectomy and pantoprazole on type 2 diabetes mellitus and beta-cell mass in Goto-Kakizaki rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Combined Modality Therapy; Diabetes Mellitus, Expe | 2018 |
Pantoprazole may improve beta cell function and diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cohort Studies; | 2014 |
Lower plasma pantoprazole level predicts Helicobacter pylori treatment failure in patients with type 2 diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Diabetes M | 2015 |
Raising serum gastrin to improve glycemic control in (type 2) diabetes: another limb of the enteroinsular axis?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; H | 2012 |